Gilead Sciences, Inc. vs Shopify Inc. — how do they compare? Gilead Sciences, Inc. trades at $136.26 (market cap $168.35B), while Shopify Inc. trades at $150.21 (market cap $196.35B). The key difference: Shopify Inc. is the larger of the two by market cap, and Gilead Sciences, Inc. pays a 2.42% dividend while Shopify Inc. pays none. Which is the better fit depends on your goals.
| GILD | SHOP | |
|---|---|---|
Market Cap | $168.35B | $196.35B |
Sector | Health | Technology |
52-Week High | $155.80 | $179.01 |
52-Week Low | $110.56 | $95.40 |
Enterprise Value | $191.42B | $191.59B |
Dividend Yield | 2.42% | — |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.
The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.
Shopify (SHOP) trades at $155.18, up 2.38% today, following strong Q2 2026 earnings beats. The stock exhibits a bullish technical trend with support at $151 and resistance at $158. Revenue growth remains robust, with 2025 revenue reaching $11.56B, though valuation multiples like a P/E of 103.11 are elevated. Positive analyst sentiment is driven by AI commerce integration and expanding gross merchandise volume.
Outlook is positive given earnings momentum and AI-driven growth, but high valuation and competitive e-commerce pressures pose risks. The consensus price target of $166.39 suggests modest upside, supported by 65.62% of analysts rating it Buy. Investors should weigh growth prospects against premium pricing.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Shopify Inc. provides a cloud-based commerce platform. The Company offers a platform for merchants to create an omni-channel experience that helps showcase the merchant's brand.
Read more on SHOP →